CoraLite® Plus 488-conjugated Apolipoprotein AI Polyclonal antibody

• Featured Product
• KD/KO Validated

Apolipoprotein AI Polyclonal Antibody for IF-P

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

IF-P

Conjugate

CoraLite® Plus 488 Fluorescent Dye

Cat no : CL488-14427

Synonyms

Apo AI, ApoA I, APOA1, apolipoprotein A I, Apolipoprotein A1

---

Validation Data Gallery

• 

  IF Staining of mouse liver using CL488-14427

  Immunofluorescent analysis of (4% PFA) fixed mouse liver tissue using CoraLite® Plus 488 Apolipoprotein AI antibody (CL488-14427) at dilution of 1:200.

---

Tested Applications

• Positive IF-P detected in: mouse liver tissue

Recommended dilution

• Immunofluorescence (IF)-P: IF-P : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

CL488-14427 targets Apolipoprotein AI in IF-P applications and shows reactivity with human, mouse samples.

• Tested Reactivity: human, mouse
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: Apolipoprotein AI fusion protein Ag5793
• Full Name: apolipoprotein A-I
• Calculated Molecular Weight: 31 kDa
• Observed Molecular Weight: 26-30 kDa
• GenBank Accession Number: BC005380
• Gene Symbol: APOA1
• Gene ID (NCBI): 335
• RRID: AB_2919091
• Conjugate: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission Maxima Wavelengths: 493 nm / 522 nm
• Form: Liquid
• Purification Method: Antigen affinity purification
• Storage Buffer: PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
• Storage Conditions: Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage.

Background Information

ApoA1 is a major protein component of high density lipoproteins (HDL) which is associated with reversed cholesterol transport, lipid/cholesterol binding, lecithin/cholesterol acyltransferase (LCAT) activation and specific receptors binding. It is synthesized in the liver and small intestine. Defects of ApoA1 cause low HDL level and systemic non-neuropathic amyloidosis. Serum concentration of ApoA1 is inversely related to the risk of developing atherosclerosis. This antibody was generated against the C-terminal region of human ApoA1.